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Report of the independent panel considering the
retraction of two articles in The BMJ
In May The BMJ corrected an error relating to adverse effects of statins in two articles but was
asked to retract the articles. The editor referred the decision to an expert panel. Here, we publish
its findings
Iona Heath panel chair and past president, Royal College of General Practitioners, Stephen Evans
professor of pharmacoepidemiology, London School of Hygiene and Tropical Medicine, Curt Furberg
professor emeritus of public health sciences, Wake Forest University School of Medicine, Julia
Hippisley-Cox professor of epidemiology and general practice, University of Nottingham, Harlan
Krumholz Harold H Hines Jr professor of medicine (cardiology) and professor of investigative
medicine and of public health, Yale School of Medicine, Cynthia Mulrow senior deputy editor, Annals
of Internal Medicine, Paul Wicks vice president of innovation, Patients Like Me
In October 2013 The BMJ published an Analysis article by
Abramson et al1 arguing that cholesterol lowering guidelines
should not be widened to include statin therapy for low risk
individuals (five year risk <10%) and an Observations article
by Malhotra2 suggesting that saturated fat is not the main cause
of cardiovascular disease. TheAbramson et al article1 questioned
the balance of risk and benefit presented in the recently updated
Cochrane review3 and the 2012 Cholesterol Treatment Trialists’
(CTT) Collaboration meta-analysis4 (on which the updates to
the 2013 Cochrane review3 are largely based). Both articles
quoted an article by Zhang et al5 to claim that the rate of side
effects with statins was around 20%. This was an error. In fact,
Zhang et al5 referred to “statin-related clinical events that may
be interpreted as adverse reactions by patients or their
clinicians.” As Zhang et al themselves pointed out in a rapid
response to Abramson et al’s article, “implicit in this definition
is the recognition that the causative association between each
identified event and statin use was unknown.”6
This error of interpretation was first suggested in a rapid
response from Takhar7 immediately after publication of the
Abramson et al article1 and subsequently clarified by Zhang et
al themselves in a letter published in June 2014.8 Numerous
rapid responses were posted, reflecting a vigorous debate on
the merits and limitations of statins for those at low risk of
cardiovascular disease.
On 30 October 2013, a few days after publication, Rory Collins,
professor of medicine and epidemiology at the Clinical Trial
Service Unit at Oxford University and an author on the
meta-analysis by the Cholesterol Treatment Trialists’ (CTT)
Collaboration published in the Lancet in 20124, sent an email
to the editor of The BMJ, Fiona Godlee, stating that the journal
seemed to have taken a stand against statins and that there was
a danger that misrepresentation of the evidence in The BMJ
could cause harm. He discussed this in person with Fiona Godlee
in December 2013 and talked her through a set of slides (later
submitted to the panel with additional annotations, SP16a on
bmj.com). At that meeting Godlee invited Collins to write an
article presenting evidence on the benefits and harms of statins:
“Although your article would be a response to the two articles,
and to Abramson et al in particular, it would be helpful if you
could use the opportunity to set your piece in the wider context
of the evidence on the benefits and harms of statins.” (See SP13,
email 2 December). Following this discussion Collins submitted
a number of written but not for publication criticisms to Godlee,
focused mainly on the Abramson et al article, and was again
invited to write an article in response. At the time of this report
he had not yet done so in the form of a submitted article.
In another letter to Godlee, marked “not for publication” and
dated 28 April 2014, Collins called for retraction of both articles,
writing: “What the BMJ needs to do is withdraw these seriously
damaging claims explicitly and unreservedly with a clear
explanation of why they are so wrong and what is likely be
correct, and to demonstrate that it is serious about rectifying the
damage that it has caused by retracting both of these papers.”
He emphasised the seriousness of his concerns, describing “the
need to rectify the harm that has been caused—perhaps resulting
in large numbers of unnecessary deaths, heart attacks and strokes
among patients at elevated risk—bymisleading doctors and the
public with gross over-estimates of the rates of side-effects with
statins.” (SP20)
On 15 May 2014, corrections were posted for both articles,
withdrawing the statement that side effects of statins occur in
about 18-20% of patients.9 10 “The authors withdraw this
statement. Although it was based on statements in the referenced
observational study by Zhang and colleagues, that ‘the rate of
reported statin-related events to statins was nearly 18%,’ the
article did not reflect necessary caveats and did not take
sufficient account of the uncontrolled nature of the study.”
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Godlee highlighted the corrections in an editorial on 15 May
2014.11
In response to the request for retraction, Godlee set up an
independent panel to consider the question of retraction and to
review the processing of the articles (www.bmj.com/content/
independent-statins-review-terms-of-reference).
She provided the panel with the following terms of reference,
outlining the specific tasks to be undertaken:
• To consider whether either or both articles should be
retracted
• To review and comment on the process by which the
articles were published
• To review and comment on how criticisms and complaints
against the articles were raised and how the journal
responded
• To summarise its findings and make recommendations to
The BMJ’s editor in chief in a report that will be published
on bmj.com.
Independence
The panel members were invited to contribute by Godlee and
all have some connection with The BMJ. All are committed to
maintaining the journal’s reputation for scientific integrity
through the correction of errors and, if necessary, through
retraction. The members of the panel have had no contact with
any of The BMJ staff about its deliberations. The journal has
not sought to influence the panel’s discussions nor had prior
notice of the findings before submission of this the final report
on 31 July 2014. The potential conflicts of interest of all the
members of the panel, including roles in The BMJ, have been
declared and are appended to this report (SP28). The members
were not offered and have not received any payment for their
service on the panel.
Grounds for retraction
The panel decided to use the 2009 Retraction Guidelines issued
by the Committee on Publication Ethics (COPE)12:
Journal editors should consider retracting a publication if:
• They have clear evidence that the findings are unreliable,
either as a result of misconduct (eg data fabrication) or
honest error (eg miscalculation or experimental error)
• The findings have previously been published elsewhere
without proper cross referencing, permission or justification
(that is, cases of redundant publication)
• It constitutes plagiarism
• It reports unethical research.
COPE also states that “Retraction is a mechanism for correcting
the literature and alerting readers to publications that contain
such seriously flawed or erroneous data that their findings and
conclusions cannot be relied upon. Unreliable data may result
from honest error or from research misconduct. Retractions are
also used to alert readers to cases of redundant publication (i.e.
when authors present the same data in several publications),
plagiarism, and failure to disclose a major competing interest
likely to influence interpretations or recommendations. The
main purpose of retractions is to correct the literature and ensure
its integrity rather than to punish authors who misbehave.”12
The panel has not found any guidelines for the retraction of
opinion pieces and could not identify any precedent for
retracting an opinion piece unless it was based on fraudulent
data. The panel noted that retraction has almost always been
reserved for papers where original data are presented.
General approach
Collins first requested retraction of the two articles in his letter
to Godlee of 31 March 2014 (SP17), six months after their
publication. In his formal submission to the panel, Collins stated
the following: “Such serious misrepresentations of the evidence
seem likely to lead to people who are at elevated risk of heart
attacks and strokes stopping their statin therapy or not starting
it in the first place. As a consequence, this may well result in
unnecessary heart attacks, strokes and vascular deaths. With
regard to the issue of offering statins to people who are at the
lower end of the risk spectrum, such misinformation about
side-effect rates would prevent them from making a properly
informed choice, although the impact is likely to be less
catastrophic.” (SP15)
The panel recognised that Analysis and Observations pieces
should provide latitude for scientists to interpret the available
data but acknowledged that wrong information should not be
presented. The question the panel set out to answer was whether
the arguments provided in the two articles were misleading in
a way that was likely to cause harm or whether they represented
alternative views that are reasonable and based on a plausible
interpretation of what is known.
The panel also noted that the individual patient level data for
the relevant trials are held in confidence by the investigators
and have not yet been made available for public scrutiny by
those who question the interpretations of the trialists.
The panel asserted the importance of not discouraging scientific
debate because of disagreements of interpretation or opinion.
Nevertheless, distortions of the evidence that amount to frank
misrepresentations should be corrected and if extreme in nature,
retracted. Journals need to protect the rights of people to express
opinions and debate the evidence while being steadfast in not
allowing facts to be misrepresented.
It is important to note that the panel has not been asked to pass
judgment on the risks and benefits of statins per se, nor on the
appropriate use of statin medication in low risk individuals.
Instead the panel has been asked to decide whether there are
sufficient grounds to require retraction of one or both of the
articles from the scientific literature. The panel has been at pains
not to take sides and not to support one view at the expense of
another.
The panel was not asked to address the question of whether a
paper on the use of statins in people at low risk might influence
patients at high risk to stop their statins unnecessarily. The
question of how patients react to “scares” is complex and
controversy in the media can feed such scares.
Nonetheless the panel also recognised that attempts to exclude
patients and citizens from scientific debate because of the
possibility that they might be harmed are not usually welcomed
by the patients and citizens affected.
Evidence received
The panel requested and received submissions from Collins as
the complainant (SP15-21) and from the authors of the two
articles (SP22-24). The panel also considered all the rapid
responses (up until 15 July 2014) relating to the original
articles1 2 and to Godlee’s editorial11 and wish to express their
appreciation of all those who contributed to the open debate.
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Thirteen researchers sent private submissions to the panel
(SP25). The chair of the panel invited the authors of each
submission to post it as a rapid response to the original article
or the editorial about the panel’s establishment in The BMJ but
most declined, preferring to have their submissions published
at the time the panel reported. These submissions have been
subject to normal legal prepublication checking, and some
statements have been redacted for legal reasons, but no
substantive changes have beenmade to the arguments presented.
The panel also reviewed the original CTT paper,4 the 2011
Cochrane review,13 the updated Cochrane review from 2013,3
all the references cited in the two articles under investigation,
and other relevant papers.
To consider whether either or both articles
should be retracted
Abramson, Rosenberg, Jewell and Wright
article
The panel recognised that this was published as an Analysis
article,1 which implies some degree of interpretation and
opinion.14 It is not an original research article or a systematic
review and is designed to provide a commentary on the existing
literature.
The panel found no suggestion of data fabrication in the
complaint or in the rapid responses. The panel also noted the
correction that had been published before the panel was
convened. The panel therefore decided to concentrate on the
issue of honest error and the possibility of miscalculation in the
article. It aimed to answer the following questions:
• Whether any inaccuracies, taken as a whole, rose to the
level of outweighing what was accurate in the article
• Whether the authors had distorted the evidence available
in such a way that the article (even with the current
corrections) was so misleading it should be retracted.
Statistical review
The panel agreed to undertake a statistical check on each
numerical statement in the Abramson et al article. This was to
be assessed by two people independently: the statistician on the
panel (SE) and an external statistician. One of the panel
members (JH-C) proposed Carol Coupland (CC), associate
professor and reader in medical statistics at the University of
Nottingham, as an additional statistician with relevant skills and
expertise in the methods and subject matter under consideration.
The article was annotated to highlight each numerical statement
(SP29). A proforma relating to each specific numerical statement
was jointly developed by SE and CC and endorsed by the panel
(SP30). Each statement was to be categorised as follows:
A to mean definitely justified on the basis of the quoted
evidence.
B to indicate that the point does not necessarily agree with
the quoted sources but where it is a matter of judgement and
could be justified.
C to mean clearly wrong and definitely misrepresenting the
quoted sources.
The calculations in the Abramson et al article were then
independently reviewed by the two statisticians with neither
seeing the submission of the other until both reports had been
completed (SP31 and 32). Their analyses were in substantial
agreement. They found that the numbers in the article by
Abramson et al1 were not clearly wrong, except for the already
acknowledged misrepresentation of Zhang et al.5 11 The authors’
use of observational data in regard to muscle and other problems
is contentious but remains a matter of opinion. Abramson et al
also state “no difference” when they mean no statistically
significant difference,1 and in the view of the panel, this is
potentially misleading. However, this sort of thing occurs so
frequently in the medical literature that it cannot be considered
grounds for retraction.
Findings
On the basis of the statistical reviews and their own reading of
the background papers, the panel concluded that the calculations
in the article had been largely sound. There were very minor
differences between the two statistical reports, and these were,
at least in part, due to some lack of clarity in the original report
of the CTT meta-analysis.4
There are two major areas of contention that are crucial to
decisions to be made by both patients and their clinicians: the
effect of statins on all cause mortality when used in primary
prevention in low risk populations, and the incidence of adverse
events.
All cause mortality—A recent editorial by Vinay Prasad in
Annals of Internal Medicine15 illustrates a fundamental problem
that has consistently concerned the panel. Prasad compared two
meta-analyses of statins in primary prevention3 16 that differed
in their statistical conclusions by less than half a percentage
point and yet reached opposite conclusions—namely that that
“statins reduce . . . total mortality” or conversely that “data . .
. showed no reduction in mortality associated with treatment
with statins.” Unfortunately, patients and clinicians have to
make decisions in the grey area between these two diametrically
opposed conclusions. The panel supports Prasad’s contention
that “The Cholesterol Treatment Trialists’ study has a robust
set of de-identified individual-patient data, which can improve
our understanding, and those data should be made widely
available.”15
Adverse events—Adverse events may be coincidental or
associated with the disease being treated and therefore not true
adverse reactions (or side effects or adverse effects) that are
directly caused by the treatment. Numerous rapid responses
underlined the discrepancy between the incidence of debilitating
adverse events experienced by patients seen in clinical practice,
who believe those events to be caused by their statin, and those
reported as statistically significant differences in randomised
clinical trials. In their detailed response to the panel, Abramson
et al noted a number of possible explanations for this
discrepancy. These include the exclusion of people with
substantial multiple comorbidity from randomised clinical trials
and the further exclusion of those who report early adverse
effects during the run-in periods such as occurred in the Heart
Protection Study.17 The report of this trial noted that this strategy
could raise “questions about the generalisability of the safety
analyses because patients may have withdrawn during the run-in
due to adverse effects caused by simvastatin.”
The panel is also aware of the history of serious adverse effects
that were not originally reported in randomised clinical trials
being revealed by subsequent meta- analyses18 or postmarketing
surveillance.19 The panel has no doubt that observational studies
have a role in the identification of both adverse events
(associated with the taking of a medication) and true adverse
reactions or side effects (known to be caused by a medication).
There have been suggestions from all parties to the current
dispute that “myopathy” may have been conflated with “muscle
pain” (myalgia) and this might lead to confusion. The panel
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Accompanying documents
Items with bold numbers indicate accompanying documents that are available at www.bmj.com/content/independent-statins-review-panel-report-0. Other numbers
simply link via the indicated URL.
1. Submissions to the Panel
From the BMJ
SP1 Article by Ambramson et al www.bmj.com/content/347/bmj.f6123
SP2 Article by Malhotra re saturated fats www.bmj.com/content/347/bmj.f6340
SP3 Zhang et al. Annals of Internal Medicine 20125
SP4 Godlee F. Editorial. BMJ 2014 www.bmj.com/content/348/bmj.g3306
SP5 Pre-publication history for Abramson et al: editors’ notes. Rest of history, including reviewers’ reports are at www.bmj.com/content/347/bmj.f6123/related
SP6 Rapid responses to Abramson et al www.bmj.com/content/347/bmj.f6123/rapid-responses
SP7+8 Post-publication correspondence between The BMJ and John Abramson
SP9 Pre-publication history for Malhotra et al: email correspondence. Rest of history is at www.bmj.com/content/bmj/suppl/2014/07/07/bmj.f6340.DC1/See_peer_
r eview_for_this_article.pdf
SP9a Attachment to email (in SP9) dated 17 October at 17.34 SP10 Rapid responses to Malhotra www.bmj.com/content/347/bmj.f6340/rapid-responses
SP11+12 Post-publication correspondence between The BMJ and Malhotra
SP13 Correspondence between Rory Collins and Fiona Godlee
SP14 Timeline prepared for The BMJ and panel
From Rory Collins and the authors
SP15 Note from Rory Collins for the panel
SP16 Supplement to note from Rory Collins for the panel
SP16a Annotated slides
SP16b Annotated version of Abramson et al (annotations by Rory Collins)
SP16c Annotated version of Malhotra (annotations by Rory Collins)
SP17 Letter to Fiona Godlee 31 March 2014, not for publication
SP18 Letter to Fiona Godlee 14 April 2014, not for publication
SP19 Letter to Fiona Godlee 25 April 2014, not for publication
SP20 Letter to Fiona Godlee 28 April 2014, not for publication
SP21 Grants to CTSU
SP22 Initial Response to Rory Collins’ submission from Abramson et al
SP23 Response to Rory Collins’ submission from Abramson et al
SP24 Response to Rory Collins’ submission from Malhotra
From others
SP25 Submissions from 13 individuals or groups
SP26 Declarations of interests by the authors of submissions (see SP25)
2. Panel documents
SP27 List of documents accompanying the report
SP28 Declarations of interests of panel members
SP29 Article by Abramson et al annotated by panel to identify statements that need statistical review
SP30 Proforma for statistical review of Abramson et al
SP31 Statistical report on Abramson et al by Stephen Evans
SP32 Statistical report on Abramson et al by Carol Coupland
agreed that this is difficult area since there is no widely accepted
standard definition for “statin associatedmusculoskeletal adverse
events,” whereas there are consensus statements for the
definition of harms relating to the assessment of some other
clinical outcomes.20 The CTT 2012 paper4 cited a review by
Armitage in 2007,21 both for its figures on myopathy and, by
inference, the definition of myopathy. Armitage defined
myopathy (and myositis) as “any muscle symptom—pain,
tenderness or weakness—accompanied by a creatine kinase
concentration greater than ten times the upper limit of normal
for the laboratory.”21Armitage also stated that myalgia “referred
to muscle pain with no rise in creatine kinase concentration to
greater than ten times the upper limit of normal.”
One source of confusion is that Abramson et al reported three
different outcomes in their article, all under a heading of
“myopathy.”1 These were “myopathy” and the information
presented was directly quoted from the CTT 20124; “muscle
pains” as reported in the National Health and Nutrition
Examination Survey22; and a retrospective cohort study reporting
“incidence of musculoskeletal disorders overall and injuries.”23
The panel thought that including three different definitions of
muscle problems, widely ranging in severity, all under a heading
of the more serious myopathy, might lead to the reader to
conflate these. However, as Abramson et al point out in their
submission to the panel (SP23), myopathy and myalgia can be
conflated in the opposite direction by referring to severe
problems as if they included milder ones and this can also lead
to misinterpretation.
Conclusion
The panel concluded that the only unequivocal error in the article
by Abramson et al1 is the misrepresentation of the Zhang et al
paper5 and considered this to be insufficient to justify retraction
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of the whole article. Nothing in the article suggested that the
authors had acted malevolently or fraudulently.
Panel’s recommendation
The panel finds that the Abramson et al1 article does not meet
the COPE criteria for retraction.
Malhotra article
This is an Observations article with the strapline “From the
heart,” communicating clearly that this was an opinion piece
open to disagreement and debate.2 The main focus of the article
is on the role of saturated fat in the aetiology of cardiovascular
disease. Most of the criticism of the article from Collins
concentrates on an error related to a secondary point. This error
concerned the interpretation andmisrepresentation of the Zhang
et al paper,5 which is peripheral to the overall thrust and
conclusion of the Malhotra article2 and which has now had a
correction posted.10
Findings
Nothing in the article suggested misconduct or that the author
had acted malevolently or fraudulently. Strong and iconoclastic
opinions are expected in opinion pieces and can enhance open
scientific debate.
Panel’s recommendation
The panel finds that the Malhotra article2 does not meet the
COPE criteria for retraction.
To review and comment on the process
by which the articles were published
The editor of The BMJ had already set in motion a review of
the process and had asked for a timeline to be prepared. This
wasmade freely available to the panel without comment (SP14).
Initial submission
The initial review process seemed appropriate and adequate. It
was done in a timely and reasonably thoughtful and careful
manner. Editors and reviewers noted several areas where the
article was potentially confusing, slanted, or incorrect, and
suggested several ways to improve its presentation.
Suggestions
Editors could consider developing guidance for internal use in
relation to when Analysis articles that contain calculations and
numerical extrapolations warrant statistical review.
Revision and publication
The review of the revision took about a month. Decision making
about its acceptability was made by the Analysis editor without
obtaining additional peer review, statistical review, or opinions
from the associate editors who had discussed the original
submission. The authors did not provide the requested detailed
letter explaining their responses to editors’ and reviewers’
comments, but their revision did seem to address most of the
comments and suggestions that had been made.
The Analysis editor thought that the revision’s “message is a
little too strong for the data presented.” She placed queries in
the manuscript asking for better specification and justification
of some sentences and requested more information (a figure or
number) for the harm side of the benefit-harm equation. A
manuscript that was copy edited by a technical editor and
included the editor’s queries was sent to authors. The authors,
who responded within 1 to 2 days, added numbers about harm
that they gleaned from the recently published article by Zhang
et al,5 and the reference to that article, and changed the fact box.
The technical editor judged the authors’ revisions acceptable.
The published manuscript included the authors’ various
contributions to the article and their potential conflicts of interest
and clearly identified in the introduction that the authors were
presenting a particular point of view, “We argue that the
evidence does not show that the benefits of statins in low risk
patients outweigh the harms and that the advice for treatment
of this group should not be changed.” Arguments that were
presentedwere generally clear, factual, and referenced (including
criticism of the limitations of trial data) except that the
presentation and the interpretation of data about adverse events
from the article by Zhang et al5 added to the manuscript at the
copy editing stage was incorrect. Methods used for the
extrapolation of total mortality data from the CTTmeta-analysis4
were only explained in a footnote to the table, and limitations
of those methods were not mentioned.
Suggestions
Senior or deputy editors should sign off revisions that include
substantive additions to an article or changes in a “fact” box.
Extra attention should be given to manuscripts that have been
noted by reviewers and editors to be controversial and
potentially slanted or one sided. Editors might consider whether
such pieces are best placed (and clearly labelled) as opinion
pieces or whether they are best placed and clearly labelled as
articles/analyses that are meant to have a more comprehensive
and, according to author instructions, “an even-handed approach
in evaluating evidence, a lucid line of argument, and a
worthwhile conclusion.”14 Although the article by Abramson et
al was not press released, that by Malhotra, which was also
clearly presenting a controversial view, was
(http://group.bmj.com/group/media/latest-
news/Time%20to%20bust%20the%20myth%20of%20saturated%20fat2019s%20role%
20in%20heart%20disease-%20says%20cardiologist.pdf). Press
releases should be used with great care in such contexts.
Editors might give extra attention to the following issues when
considering potentially controversial articles that postulate strong
arguments: possible selective citing of material, failure to
critically appraise evidence that is used to support authors’
arguments, and over criticism of evidence that does not support
authors’ arguments.
Editors should carefully consider whether articles that include
extrapolations and recalculations of numerical data need
statistical review. They should also consider whether a article
that has been revised requires additional peer review.
Rapid responses
The journal received several rapid responses that raised
substantive criticisms and discussion of the Analysis article.
The editors’ selections of rapid response letters that were
directed to John Abramson for further response and discussion
were appropriate. Editors’ decision making about those
selections and their follow-up was executed in a timely manner.
Abramson and colleagues responded to the selected letters
promptly.
Corrections
The BMJ and all authors formally corrected statements in both
articles and the summary box that said that side effects of statins
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occur in 18-20% of people, and stated that “The BMJ articles
did not reflect necessary caveats and did not take sufficient
account of the uncontrolled nature of Zhang and colleagues’
data.” Godlee wrote in her editorial announcing the corrections
that “This editorial aims to alert readers, the media, and the
public to the withdrawal of these statements so that patients
who could benefit from statins are not wrongly deterred from
starting or continuing treatment because of exaggerated concerns
over side effects.”11 She also wrote that the initial submission
of the article by Abramson et al included a reference to the
Zhang article5 and a “misreading of Zhang and colleagues’ data
that was not picked up by the peer reviewers or editors.” In fact,
the Zhang reference5 was not included in the initial submission
(it was added at the proof stage) and this statement was
subsequently corrected.24 An alert drawing attention to the
corrections was inserted. Subsequently, Zhang et al sent a rapid
response that further clarifies the continuing misinterpretation
of their article.6
Assessment
Editors used due diligence in assessing the necessity for
corrections, and made important corrections that are clearly
labelled. The statement “not picked up by peer reviewers” was
an error which was also corrected.
Panel’s conclusion
The panel has made several suggestions aimed at improving the
editorial process and was concerned about the late inclusion of
an unscrutinised reference on a short timescale. However, the
panel concedes that the peer review and editorial processes must
rely on goodwill to a very considerable extent and can never be
completely foolproof—especially in view of the time pressures
under which authors, peer reviewers, and editors are working.
To review and comment on how criticisms
and complaints against the articles were
raised, and how the journal responded
The panel had access to all the correspondence between Collins
and Godlee (SP13), in addition to the other submissions already
noted.
Findings
The panel noted with concern that despite the editor’s repeated
requests that Collins should put his criticisms in writing as a
rapid response, a letter to the editor, or as a standalone article,
all his submissions were clearly marked “not for publication.”
The panel considered this unlikely to promote open scientific
dialogue in the tradition of The BMJ.
The delay in responding to criticism from Collins was not from
October 2013 to May 2014, as he stated publicly after the
correction appeared on 15May 2014, because in an email dated
30 January 2014 he indicated that he was preparing an article
responding to Abramson et al (SP13); this had yet to be
submitted at the time of the panel’s report. In a BBC Radio 4
Today interview on 21 March 2014 (SP14), he again referred
to the fact that he was writing an article clarifying the evidence.
He did not formally submit his concerns in writing to The BMJ
until the end of March 2014 (SP17), by which time he had
already complained about The BMJ’s delay in responding and
had shared his views with the mainstream media. On this basis,
the delay cannot be considered to be longer than from March
2014 to May 2014.
However, there was a delay from October 2013 to May 2014
in correcting the misinterpretation in relation to the Zhang et
al5 citation, which was indicated in the rapid responses on the
day the Abramson article1 appeared in print. Takhar7wrote: “the
final point in key messages box . . . is not conclusively backed
up by the detailed evidence and references presented.” Abramson
et al responded to Takhar in their own rapid response, and this
may have reassured the editorial staff.
Panel’s conclusion
The BMJ editorial staff should implement a significant event
audit in relation to the need for the correction. The aim of the
audit would be to try to identify what would need to have been
in place to ensure that the correction was made in a more timely
fashion.
Summary of conclusions and
recommendations
The parties to this latest controversy over the role of statin
medication in the primary prevention of cardiovascular disease
have different professional backgrounds and experience, which
results in different perspectives, interpretations, and judgments.
Unbiased groups of scientific investigators analysing the same
data can reach very different conclusions.
The panel was unanimous in its decision that the two articles
do not meet any of the criteria for retraction. The error did not
compromise the principal arguments being made in either of
the articles. These arguments involve interpretations of available
evidence and were deemed to be within the range of reasonable
opinion among those who are debating the appropriate use of
statins. In making this assessment, the panel is not expressing
an opinion about the merits of these arguments, as that work
was beyond the scope of the panel.
The panel did have one final comment. It became clear to the
panel that the fact that the trial data upon which this controversy
is based are held by the investigators and not available for
independent assessment by others may contribute to some of
the uncertainty about risks and benefits. Different investigators
may come to different conclusions with the same data. In fact,
a particularly germane example occurred recently in which two
experienced Cochrane groups were charged with evaluating a
particular intervention and, despite being given the same
instructions, data, and resources, did not arrive at identical
results or conclusions.25 26 The panel strongly believes that the
current debates on the appropriate use of statins would be
elevated and usefully informed by making available the
individual patient level data that underpin the relevant studies
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